Incretin-based Drugs Market Size & Share 2026-2035

Incretin-based Drugs Market Size

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by the rising prevalence of type 2 diabetes mellitus, a shift toward non-insulin therapies, advancements in drug delivery technologies, and cardiovascular and weight management benefits.
 

The market increased from USD 35.5 billion in 2023 to USD 37.4 billion in 2024. The rapidly increasing prevalence of type 2 diabetes mellitus is a major factor accelerating the growth of the global incretin-based drugs market. According to the World Health Organization (WHO), the number of people living with diabetes surged from 200 million in 1990 to 830 million in 2022, representing a dramatic rise driven largely by lifestyle changes, urbanization, and aging populations.
 

Importantly, over 95% of all diabetes cases are type 2 diabetes, highlighting its dominance as a global metabolic health challenge. This expanding patient pool has created significant demand for effective and safer glucose-lowering therapies that manage hyperglycemia and also address comorbidities such as obesity, cardiovascular disease, and metabolic syndrome.
 

Incretin-based drugs, including GLP-1 receptor agonists and DPP-4 inhibitors, have become increasingly preferred due to their ability to enhance insulin secretion, reduce glucagon levels, support weight management, and offer cardiovascular benefits. As T2DM continues to rise across both developed and emerging markets, healthcare providers and policymakers are shifting toward these advanced therapies. This trend is expected to sustain strong market growth in the coming years, driven by expanding treatment adoption, improved clinical outcomes, and rising awareness of incretin-based interventions.
 

Additionally, the growing recognition of cardiovascular and weight management benefits associated with incretin-based therapies, especially GLP-1 receptor agonists, is emerging as a major driver for the incretin-based drugs market. Beyond their glucose-lowering effects, GLP-1 analogs have demonstrated significant reductions in major adverse cardiovascular events, making them preferred treatment options for patients with type 2 diabetes who are at high cardiovascular risk. Their ability to lower blood pressure, improve lipid profiles, and reduce inflammation further strengthens their clinical value in cardiometabolic care. Weight reduction has become equally important for the growth of the market.
 

According to the World Health Organization (WHO), in 2022, 1 in 8 people globally were living with obesity, reflecting a rapidly expanding patient population seeking effective metabolic and weight-management solutions. Incretin-based drugs, such as semaglutide and liraglutide, produce clinically meaningful weight loss by reducing appetite and slowing gastric emptying. This dual benefit addressing both obesity and cardiovascular risk makes them highly attractive to healthcare providers and patients. As the global burden of obesity and cardiometabolic disease continues to rise, the adoption of incretin-based therapies is accelerating, driving substantial growth in the market across both diabetes care and weight-management segments.
 

Incretin-based drugs are a class of glucose-lowering therapies that mimic or enhance the action of natural incretin hormones, primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), to improve insulin secretion, suppress glucagon release, slow gastric emptying, and support weight loss in patients with type 2 diabetes and obesity.

Incretin-based Drugs Market Trends

• The incretin‑based drugs industry is experiencing strong growth due to continuous progress in drug delivery technologies, which is enabling the development of more effective and patient‑friendly treatments. New delivery approaches, such as oral GLP‑1 formulations and extended‑release injectables, have significantly boosted treatment adherence and improved clinical outcomes. The availability of once‑weekly GLP‑1 receptor agonists has particularly enhanced patient convenience and disease management.
   
• For example, in December 2024, the U.S. FDA authorized the first generic version of Victoza (liraglutide 18 mg/3 mL), approved for improving glycemic control in adults and children aged 10 years and above with type 2 diabetes when combined with diet and exercise.
   
• Additionally, ongoing research is also exploring alternative, less invasive delivery routes. Technologies like microneedle patches and implantable depots are being designed to provide slow and steady drug release, reducing injection frequency and helping maintain stable blood glucose levels. In addition, MIT scientists have created an ingestible capsule capable of transporting medications, including GLP‑1 drugs, directly into the bloodstream, presenting a promising oral substitute for injections and making diabetes and obesity therapies more accessible.
   
• Furthermore, combination therapies are transforming metabolic care by targeting multiple pathways simultaneously. Tirzepatide (Mounjaro), a dual GLP‑1/GIP agonist, demonstrates superior blood sugar reduction and weight loss compared to single‑target GLP‑1 drugs, expanding treatment options and offering enhanced outcomes for patients managing diabetes and obesity.
   

Incretin-based Drugs Market Analysis

Based on drug type, the incretin-based drugs market is segmented into GLP-1 receptor agonists and DPP-4 inhibitors. The GLP-1 receptor agonists segment was valued at USD 25.7 billion in 2025.
 

• GLP‑1 receptor agonists continue to gain strong traction in the market due to their proven clinical performance and broad therapeutic relevance across diabetes and obesity care. Their dominance is reinforced by the success of semaglutide‑based therapies, which continue to set benchmarks for efficacy, patient outcomes, and market adoption. Leading companies have built a robust global presence through innovative GLP‑1 products, helping establish these therapies as essential components of modern metabolic disease management.
   
• Demand for GLP‑1 receptor agonists is further accelerated by the growing global burden of type 2 diabetes. According to the World Health Organization, more than 90% of individuals with diabetes are affected by type 2 diabetes, underscoring the urgent need for effective glucose‑lowering therapies. GLP‑1 receptor agonists directly address this demand by enhancing insulin secretion, reducing glucagon release, and preventing post‑meal glucose spikes.
   
• In addition to their glucose‑regulation benefits, GLP‑1 receptor agonists are increasingly adopted for their meaningful impact on weight management, a key factor in metabolic disease progression. By reducing appetite and slowing gastric emptying, these therapies support sustained weight loss and improved long‑term metabolic health. Their combined benefits in both glycemic control and obesity management have positioned GLP‑1 drugs as preferred options among clinicians seeking comprehensive solutions for complex metabolic conditions.
   
• Furthermore, the market is experiencing strong momentum due to advancements in drug delivery technologies, particularly the emergence of longer‑acting formulations. Once‑weekly GLP‑1 injections have significantly enhanced patient convenience and adherence, driving wider acceptance across diverse patient groups. As manufacturers continue to develop more accessible, durable, and patient‑friendly delivery systems, the adoption of GLP‑1 receptor agonists is expected to rise further, reinforcing their market leadership and supporting sustained growth in the market.
   

Based on the route of administration, the incretin-based drugs market is bifurcated into oral and injectable. The oral segment accounted for a revenue share of 76.7% in 2025.
 

• Oral incretin‑based therapies offer a convenient alternative to injectable options, which contributes to better patient adherence. Additionally, continuous progress in developing oral incretin formulations has enhanced their effectiveness, safety, and overall user adherence.
   
• For instance, Lilly’s oral GLP‑1 candidate, orforglipron, has strengthened the outlook for the oral incretin‑based drugs segment by proving that a pill can deliver efficacy comparable to injectable GLP‑1 therapies. In its successful Phase 3 trial, the molecule achieved statistically significant A1C reductions and demonstrated a safety profile aligned with injectable treatments. It also produced meaningful weight loss at higher doses, reinforcing its therapeutic value. These results highlight the potential of oral GLP‑1 options to expand patient access and accelerate adoption within the market.
   
• These oral medications are simpler to transport, store, and administer, making them suitable for a wide range of healthcare environments. Because they do not require specialized training for self‑administration, they also help reduce the workload on healthcare professionals.
   
• Moreover, patients generally favor oral therapies due to their ease and convenience, which further supports the expanding use of oral incretin‑based drugs in diabetes management.
   

Based on indication, the incretin-based drugs market is segmented into type 2 diabetes mellitus, obesity and weight management, and other metabolic disorders. The type 2 diabetes mellitus segment dominated the market with the largest revenue of USD 28.1 billion in 2025.
 

• The global rise in type 2 diabetes, largely influenced by increasing obesity rates, unhealthy eating patterns, and limited physical activity, continues to create a steady need for reliable treatment options such as incretin‑based therapies. Projections from the IDF Diabetes Atlas indicate that diabetes cases will continue climbing sharply, with hundreds of millions of people expected to be affected in the coming decades.
   
• The expanding patient base highlights the urgency for advanced and effective therapeutic interventions, making incretin‑based medications increasingly relevant in modern diabetes care.
   
• These therapies offer targeted action by stimulating insulin secretion only when blood glucose levels rise, reducing the likelihood of sudden drops in blood sugar. This mechanism provides a safer therapeutic option for many individuals. Such benefits are particularly valuable for older adults and patients more vulnerable to severe hypoglycemia, providing a dependable and well‑tolerated approach to glucose management.
   
• Overall, the continued escalation of diabetes prevalence reinforces the important role of incretin‑based drugs in addressing both current and future treatment demands.

Based on distribution channel, the incretin-based drugs market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 20.1 billion in 2025.
 

• Hospital pharmacies play a crucial role in supporting the use of incretin‑based therapies, as patients in these settings often require specialized medical attention. These environments provide controlled and secure access to medications, ensuring that individuals who are newly diagnosed or managing more complex cases receive the oversight needed for safe and effective treatment.
   
• Additionally, hospital pharmacists guide patients through the proper use of incretin‑based drugs, explaining potential side effects and differences between available formulations. Their personalized counselling helps patients understand when oral options might be preferable or when injectable versions are recommended for optimal diabetes or weight‑management outcomes.
   
• These facilities also extend comprehensive support services, including medication management programs, close monitoring of therapeutic progress, and coordination with multidisciplinary care teams. This integrated approach improves patient adherence and enhances the success of prescribed treatment plans, contributing positively to overall market growth.
   
• Furthermore, hospital pharmacies contribute to better clinical outcomes by ensuring that treatment adjustments are made promptly and accurately. Their involvement reduces medication errors, provides continuity of care, and ensures that patients transition smoothly between hospital and outpatient settings without disruption in therapy.
   
• Hospital‑based pharmaceutical teams often participate in institutional protocols and therapeutic committees, promoting evidence‑based use of incretin drugs. Their role in policy development, formulary decisions, and clinical education strengthens healthcare system readiness and supports wider adoption of these therapies across diverse patient populations.

North America Incretin-based Drugs Market

North America accounted for 45.7% of the global incretin-based drugs industry in 2025. The market in North America is experiencing robust expansion, driven by the increasing prevalence of type 2 diabetes.
 

• The rising prevalence of type 2 diabetes mellitus is strengthening demand for incretin‑based drugs across North America. A growing patient population is increasing the need for effective therapies that support long‑term blood‑glucose control and offer additional benefits such as weight management. Healthcare providers are using incretin‑based treatments more widely as they look for reliable options to manage the chronic nature of the disease.
   
• According to the Government of Canada, type 2 diabetes is the most common form of diabetes in the country, representing approximately 90% to 95% of all cases. Diagnoses most often occur in older adults, with more than 80% identified after the age of 40. This trend highlights the expanding treatment requirement within an aging population and supports stronger uptake of incretin‑based therapies.
   
• Growing lifestyle‑related risks, including obesity and limited physical activity, continue to increase the number of individuals developing type 2 diabetes across the region. Broader screening efforts and earlier detection are also expanding the treated patient base. These factors together create steady momentum for the incretin‑based drugs market in North America, reinforcing its long‑term growth prospects.
   
• The increasing prevalence of type 2 diabetes mellitus in the U.S. is shaping a strong demand environment for incretin‑based therapies. A rising number of diagnosed patients is pushing healthcare providers to adopt treatment options that deliver sustained glycemic control, weight‑management benefits, and broader metabolic support. This shift is strengthening the market position of GLP‑1 receptor agonists and DPP‑4 inhibitors as essential components of modern diabetes management in the U.S.
   
• For instance, according to the American Diabetes Association, an estimated 364,000 Americans under age 20 are living with diagnosed diabetes, representing around 0.45% of that age group. In 2022 alone, the U.S. recorded 14,490 new cases of type 2 diabetes in individuals younger than 18. The increasing presence of type 2 diabetes in youth is creating a long‑term demand path for advanced therapies, reinforcing the relevance of incretin‑based drugs across age groups.
   
• Broader lifestyle‑driven risk factors, rising obesity rates, and earlier onset of metabolic disorders are intensifying the pressure on the healthcare system to expand access to effective antidiabetic medicines. Screening initiatives and proactive management programs also identify patients earlier, contributing to steady growth in therapy initiation. These combined trends are supporting a sustained expansion trajectory for the U.S. market.
   

Europe Incretin-based Drugs Market

Europe's incretin-based drugs industry accounted for USD 8.1 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Growing clinical preference for non‑insulin therapies is becoming a significant catalyst for the expansion of the Europe incretin‑based drugs market. Healthcare providers across the region are increasingly prioritizing treatment options that support glucose control while reducing the risks associated with insulin initiation, such as hypoglycemia and weight gain. This transition is positioning GLP‑1 receptor agonists and DPP‑4 inhibitors as preferred early‑line and add‑on therapies within modern diabetes care pathways.
   
• Improving clinical guidelines and broader physician confidence continue to strengthen momentum for these non‑insulin approaches. European health authorities and professional associations are recommending earlier use of incretin‑based treatments to help delay or minimize the need for insulin in eligible patients.
   
• The shift is also driven by rising patient preference for simpler, lower‑risk regimens that can be incorporated into everyday life without the burden of insulin titration. Increasing awareness of the cardiometabolic benefits offered by specific incretin‑based therapies is accelerating this change, reinforcing adoption across primary and specialty care settings. Combined, these factors contribute to a sustained transition toward non‑insulin diabetes management in Europe.
   

UK incretin-based drugs market is projected to experience steady growth between 2026 and 2035.
 

• The UK incretin‑based drugs industry is expected to gain momentum as government efforts intensify around improving diabetes management. National health authorities are actively promoting early detection, preventive care, and healthier lifestyle choices through targeted public‑health campaigns and updated clinical guidelines. These initiatives are reinforcing the shift toward structured diabetes care pathways, indirectly supporting the adoption of advanced treatment options such as incretin‑based therapies.
   
• Growing rates of type 2 diabetes across the country are also contributing to this demand. Higher incidence levels are strongly associated with rising obesity and increasingly sedentary lifestyles, which continue to challenge public health systems. The need for effective glucose‑lowering medications is expanding accordingly, and incretin‑based drugs are emerging as a preferred option due to their metabolic and weight‑related benefits.
   
• Government health data highlights the scale of the issue. The Health Survey for England reported that in 2021, 25.9% of adults were classified as obese, while 37.9% were overweight. This widespread prevalence of weight‑related risk factors illustrates a growing population vulnerable to type 2 diabetes, reinforcing the importance of accessible therapeutic solutions such as incretin-based drugs across the region.
   

Asia Pacific Incretin-based Drugs Market

The Asia Pacific region is projected to show a lucrative growth of about 6.7% during the forecast period.
 

• Growing recognition of the cardiovascular and weight‑management advantages offered by incretin‑based therapies is becoming a key driver of market growth across the Asia‑Pacific region. Healthcare providers are increasingly prioritizing treatments that address not only glycemic control but also the broader metabolic risks associated with type 2 diabetes. GLP‑1 receptor agonists, in particular, are gaining traction due to their proven ability to reduce cardiovascular complications while supporting meaningful weight reduction, two clinical outcomes that align closely with evolving therapeutic guidelines in the region.
   
• The rising burden of obesity among children and adolescents is further shaping treatment priorities. According to OECD, obesity rates vary significantly, reaching 22.1% in Brunei Darussalam and 17.8% in New Zealand. This early‑life exposure to excess weight increases long‑term vulnerability to metabolic disorders, thereby expanding the potential future patient base requiring therapies with strong weight‑management profiles. These trends are reinforcing the relevance of incretin‑based drugs as countries look to integrate more comprehensive interventions that address the root causes of diabetes progression.
   

India incretin-based drugs market is poised to witness lucrative growth between 2026 – 2035.
 

• The steady rise in diabetes prevalence among adults in Japan continues to strengthen the demand for advanced therapeutic options, such as incretin‑based drugs. The adult diabetic population has grown substantially over the past two decades, from 7.1 million in 2000 to 10.7 million in 2011, reaching 10.8 million in 2024, and projected to remain high at 9.4 million by 2050. This sustained burden highlights the ongoing need for innovative treatments capable of supporting long‑term metabolic management across an aging population.
   
• Furthermore, heightened awareness has led to a more proactive healthcare environment, where the emphasis is on comprehensive disease management and minimizing long‑term complications. These shifts support wider adoption of incretin‑based therapies, given their dual benefits in glycemic control and broader metabolic outcomes.
   
• Japan’s strong pharmaceutical landscape further contributes to market expansion. Several leading domestic companies are deeply involved in the research and development of advanced antidiabetic medications, including next‑generation incretin‑based drugs. Their continued innovation, combined with sustained clinical demand, reinforces the growth outlook for the market in Japan.
   

Latin America Incretin-based Drugs Market

Brazil is experiencing significant growth in the incretin-based drugs industry.
 

• A growing shift toward non‑insulin therapies is influencing the growth of Brazil’s incretin‑based drugs market. Healthcare professionals are increasingly choosing treatment options that avoid the common challenges associated with insulin, including hypoglycemia, weight gain, and complicated dose adjustments. This preference is supporting greater use of GLP‑1 receptor agonists and DPP‑4 inhibitors, which offer convenient administration, strong safety profiles, and additional metabolic benefits that align with evolving clinical practices in the country.
   
• Rising awareness of cardiovascular and metabolic health, combined with an expanding population diagnosed with type 2 diabetes, is further strengthening this movement. Patients are seeking therapies that contribute to weight management and reduce overall cardiometabolic risk, making incretin‑based medications a suitable fit for long‑term care. As clinical guidelines gradually emphasize earlier adoption of these non‑insulin options, Brazil is experiencing consistent market growth, reinforcing the role of incretin‑based drugs in modern diabetes management.
   

Middle East and Africa Incretin-based Drugs Market

• The rising prevalence of type 2 diabetes in Saudi Arabia is becoming a major factor driving the demand for incretin‑based therapies. Rapid lifestyle changes, including higher rates of obesity, physical inactivity, and dietary shifts toward calorie‑dense foods, have significantly increased the number of individuals developing type 2 diabetes.
   
• As the patient population continues to expand, healthcare providers are prioritizing treatment options that support long‑term glycemic control while addressing broader metabolic risks, strengthening the adoption of GLP‑1 receptor agonists and DPP‑4 inhibitors.
   
• The government’s focus on improving chronic disease management through national health programs and preventive‑care initiatives is shaping a more structured approach to diabetes treatment. Incretin‑based drugs, with their advantages in glucose regulation and weight management, are well‑positioned to meet these evolving healthcare priorities, reinforcing their role in Saudi Arabia’s expanding diabetes care landscape.
   

Incretin-based Drugs Market Share

• The leading players in the incretin‑based drugs industry, including Novo Nordisk, Eli Lilly and Company, Takeda, Merck, and Sanofi, collectively hold an estimated 35% share of the global market. Novo Nordisk and Eli Lilly dominate this share due to their strong GLP‑1 and dual‑agonist drug portfolios, while Takeda, Merck, and Sanofi maintain a solid presence through ongoing R&D investments and expansion in metabolic‑disease therapeutics.
   
• Leading companies in the incretin‑based drugs market are significantly increasing investments in next‑generation therapeutic technologies to improve glycemic control, weight management, and long‑term metabolic outcomes. Key areas of innovation include AI‑driven drug discovery platforms, advanced peptide engineering, and novel delivery systems such as once‑weekly injectables, oral formulations, and long‑acting GLP‑1/GIP agonists. These advancements aim to enhance efficacy, reduce side effects, improve patient adherence, and lower the overall burden of diabetes and obesity management.
   
• Through strategic acquisitions, partnerships, and global expansion initiatives, major players are reinforcing their presence across the incretin-based therapeutics ecosystem. Collaborations with pharmaceutical manufacturers, clinical research institutions, digital health platforms, obesity‑care providers, and endocrinology centers are widening access to advanced GLP‑1, GIP, and dual‑agonist therapies, especially across high‑growth emerging markets.
   
• This integrated commercialization and care‑delivery approach ensures timely treatment initiation, improved continuity of care, optimized dosing, and better adherence support for patients with type 2 diabetes, obesity, and cardiometabolic disorders.
   

Incretin-based Drugs Market Companies

Few of the prominent players operating in the incretin-based drugs industry include:

• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly and Company
• Merck
• Novo Nordisk
• Pfizer
• Sanofi
• Takeda Pharmaceutical Company
• Teva Pharmaceuticals
   
• AstraZeneca

AstraZeneca holds key position in the market through its GLP-1 receptor agonist (Byetta and Bydureon) and DPP-4 inhibitors (Onglyza). The company thus has diversified presence across key incretin drug types. Byetta and Bydureon were initially introduced for Type 2 diabetes, whereas Onglyza an oral agent helps in improving glycaemic control. Availability of these commercialized incretin-based therapies in injectable and oral drug formats enables AstraZeneca to strongly compete in the market.
 

• Sanofi

Sanofi remains an important player in the incretin‑based drugs market, leveraging its long-standing diabetes expertise, global presence, and strong clinical partnerships. Its focus on metabolic research, patient‑centric therapies, and evidence-backed treatment approaches reinforces its credibility and ensures continued relevance in advancing incretin‑driven metabolic care.
 

• Teva Pharmaceuticals

Teva Pharmaceuticals contributes to the incretin‑based drugs market through its strategic emphasis on accessible, high‑quality therapeutics, investment in complex‑generic and biosimilar development, and commitment to expanding treatment availability across global markets. Leveraging its deep expertise in formulation science, large‑scale manufacturing, and commercialization, the company supports broader patient access to incretin‑related therapies and enhances competition within the rapidly evolving cardiometabolic treatment landscape.
 

Incretin-based Drugs Industry News:

• In September 2025, Pfizer announced it had entered a definitive agreement to acquire Metsera, a clinical‑stage developer advancing next‑generation obesity and cardiometabolic therapies. The acquisition expanded Pfizer’s metabolic pipeline with differentiated incretin, non‑incretin, and combination‑therapy candidates, reinforcing its strategic focus on cardiometabolic innovation. The move strengthened Pfizer’s competitive position and enhanced its market presence within the rapidly growing incretin‑based therapeutic landscape.
   

The incretin-based drugs market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion and from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• GLP-1 receptor agonists
• DPP-4 inhibitors

Market, By Route of Administration

• Oral
• Injectable

Market, By Indication

• Type 2 diabetes mellitus
• Obesity and weight management
• Other metabolic disorders  

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce
   

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE